Results 21 to 30 of about 8,127 (167)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program

Current Oncology, 2022
Ribociclib plus an aromatase inhibitor and ovarian function suppression is the preferred first-line option for pre-/perimenopausal women with hormone receptor-positive/human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer.
Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni, Laura Vannini, Carlo Arcara, Gabriella Moretti, Marco Gunnellini, Luigi Coltelli, Francesco Verderame, Lorenzo Livi, Giuseppina Sanna, Donatella Grasso, Giulia Abbinante, Francesca Ragni   +16 more
doaj   +1 more source

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence

Saudi Pharmaceutical Journal, 2022
Background: The main aim of this study was to investigate the cost-effectiveness of Ribociclib in the treatment of patients with breast cancer by assessing the published evidence.
Wedad H. Alotaibi, Majd M. Alhamdan, Bander Balkhi   +2 more
doaj   +1 more source

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

Therapeutic Advances in Medical Oncology, 2020
Background: This analysis evaluated patient-reported outcomes (PROs) to assess health-related quality of life (HRQoL) in the phase III MONALEESA-7 trial, which previously demonstrated improvements in progression-free survival (PFS) and overall survival ...
Nadia Harbeck, Fabio Franke, Rafael Villanueva-Vazquez, Yen-Shen Lu, Debu Tripathy, Louis Chow, Govind K Babu, Young-Hyuck Im, David Chandiwana, Anil Gaur, Brad Lanoue, Karen Rodriguez-Lorenc, Aditya Bardia   +12 more
doaj   +1 more source

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

BMC Cancer, 2022
Introduction Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms.
Kadir Eser, Arif Hakan Önder, Emel Sezer, Timuçin Çil, Ali İnal, Banu Öztürk, Vehbi Erçolak, Berna Bozkurt Duman, Halil Çelik, Tolga Köşeci, Oğuzhan Kesen   +10 more
doaj   +1 more source

PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study [PDF]

, 2023
Introduction: In this study, the toxicities and management of palbociclib and ribociclib in older patients (≥65 years) with metastatic breast cancer patients were investigated.
Ali İnal, Kaçan, Turgut, Abdullah Sakin, Özdemir, Özlem, Simşek, Eda Tanrıkulu, Yıldırım, Hasan Çağrı, Şeber, Erdoğan Selçuk, Yusuf Karakaş, Özden Özer, Mandel, Nil Molinas, Özkan Alan, Rukiye Arıkan, Murat Araz, Sakin, Abdullah, Karakaş, Yusuf, Molinas Mandel, Nil, Koçak, Mehmet Zahid, Eda Tanrıkulu Şimşek, Hasan Çağrı Yıldırım, Seher Yıldız Tacar, Özlem Özdemir, Alan, Özkan, Özer, Özden, Ürün, Müslih, Nil Molinas Mandel, İriağaç, Yakup, Avcı, Okan, Ocak, Birol, Özlem Aydın İsak, Arıkan, Rukiye, Demir, Hacer, Teoman Şakalar, Ezgi Değerli, Onur Eşbah, Şakalar, Teoman, Çavdar, Eyyüp, Turgut Kaçan, Ersoy, Mustafa, Isak, Özlem Aydın, İnal, Ali, Erdoğan Selçuk Şeber, Hacer Demir, Karaboyun, Kubilay, Değerli, Ezgi, Okan Avcı, Deniz, Gülhan İpek, Şenocak Taşçı, Elif, Sinem Akbaş, Türker, Sema, Akbaş, Sinem, Müslih Ürün, Halil Taşkaynatan, Tasçı, Elif Şenocak, Yakup İriağaç, Gülhan İpek Deniz, Yıldız Tacar, Seher, Taşkaynatan, Halil, Aydın İsak, Özlem, Sercan Ön, Sema Türker, Ön, Sercan, İpek Deniz, Gülhan, Kubilay Karaboyun, Tanrıkulu Şimşek, Eda, Birol Ocak, Mehmet Zahid Koçak, Tacar, Seher Yıldız, Eyyüp Çavdar, Araz, Murat, Mustafa Ersoy, Elif Şenocak Taşçı, Eşbah, Onur   +71 more
core   +3 more sources

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

Breast Cancer Research, 2023
Background The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor–positive, human epidermal growth ...
P. Neven, P. A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G. V. Bianchi, M. Martín, A. Nusch, G. S. Sonke, L. De la Cruz-Merino, J. T. Beck, J. P. Zarate, Y. Wang, A. Chakravartty, C. Wang, D. J. Slamon   +17 more
doaj   +1 more source

Ribociclib plus fulvestrant in the treatment of breast cancer.

, 2021
peer reviewedINTRODUCTION: Endocrine therapy (ET) is a standard first-line treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
Sonke, Gabe S., Jerusalem, Guy, Neven, Patrick   +2 more
core   +1 more source

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

Frontiers in Oncology, 2021
PurposeTo evaluate the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced breast cancer from the US payer perspective ...
Eunae Jeong, Changjun Wang, Leslie Wilson, Lixian Zhong, Lixian Zhong   +4 more
doaj   +1 more source

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer [PDF]

, 2020
The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer.
Saeki, T, Ishikawa, T, Ito, Y, Fei Su, Mihaela Gazdoiu, Yu Han, Kim, SJ, Norikazu Masuda, Masuda, N, Yan Ji, Toyama, T, Tatsuya Toyama, Gounaris, I, Su, F, Yoon‐Sim Yap, Yap, YS, Ioannis Gounaris, Saito, M, Joanne Chiu, Toshiaki Saeki, Tomoyuki Aruga, Ji, Y, Takashi Ishikawa, Gazdoiu, M, Seung Jin Kim, Chiu, J, Aruga, T, Yoshinori Ito, Han, Y, Mitsue Saito   +29 more
core   +1 more source

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2− early breast cancer

Therapeutic Advances in Medical Oncology, 2023
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer.
Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi   +24 more
doaj   +1 more source